A 101 video on Covid-19
Here: Food for thought. END
Insane Scaremongering on a Colossal Scale
JVL: If we take the CFR for COVID-19 to be 2% . . . it’s a low estimate . . . in order to exceed Barry‘s limit* of 200,000 deaths in the US there would have to be over 10 million cases in the US. Wikipedia says the 2019 estimated population of the US is about 328 million so that means about 3% of the population would have to be diagnosed. It’s impossible to say, now, of course, but I’d be inclined to think that it’s fairly likely that 3% of the US population will get infected. We’ll see . . . . JVL says “it’s fairly likely that” around 3% of the US population of 328,000,000 will contract COVID Read More ›
Interview with Winston Ewert
The promised interview has arrived! Bob Murphy interviews Winston Ewert on various topics around Intelligent Design, including Winston’s latest paper on life’s dependency graph.
Fake stats debunker Ioannidis on COVID-19 stats: Not reliable
String theory as both “dream” and “nightmare”
Could we bring back extinct plants?
Michael Egnor to Jerry Coyne: God’s existence can be shown by science methods
Are we living in a vast bubble? Rob Sheldon explains
When the Woke meet up with Darwin…
The Darwinians show their lovely faces in Brazil
Michael Egnor: How a neuroscientist imaged free will (and “free won’t”)
The College Board Exams (Darwin-only evolution) meets COVID-19
BREAKING: Is the 1934 Bayer anti-malarial, Chloroquine, a potential Covid-19 breakthrough treatment?
And, why is that (which was announced yesterday by Mr Trump) not top- of- fold headline news everywhere? Bayer, US, has announced, March 19: >>Bayer today announced it is joining the U.S. Government’s fight against COVID-19 with a donation of 3 million tablets of the drug Resochin (chloroquine phosphate). Resochin, a product discovered by Bayer in 1934 and indicated for prevention and treatment of malaria, also appears to have broad spectrum antiviral properties and effects on the body’s immune response. New data from initial preclinical and evolving clinical research conducted in China, while limited, shows potential for the use of Resochin in treating patients with COVID-19 infection. Bayer in recent days has been in talks with the White House, HHS, Read More ›